

July 27, 2012

For Immediate Release

Company name Otsuka Holdings Co., Ltd.
Representative Tatsuo Higuchi
President and Representative Director, CEO
Code number 4578 First Section , Tokyo Stock Exchange
Inquiries Takuma Kimura
Director, Investors Relations Department

**OTSUKA RECEIVES COMPLETE RESPONSE LETTER FOR EXTENDED-RELEASE
INJECTABLE SUSPENSION OF ARIPIPRAZOLE**

Otsuka Pharmaceutical Co. Ltd., a subsidiary of Otsuka Holdings Co., Ltd., and H. Lundbeck A/S today announced receipt of a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) to Otsuka's New Drug Application (NDA) for its investigational intramuscular (IM) depot formulation of aripiprazole.

The impact of this matter on consolidated results of Otsuka Holdings is immaterial and there are no changes to the consolidated business forecast for fiscal 2012 announced by the Company on May 11, 2012.

(Tokyo, Japan and Copenhagen, Denmark, July 27, 2012) – Otsuka Pharmaceutical Co., Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced receipt of a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) to Otsuka's New Drug Application (NDA) for its investigational intramuscular (IM) depot formulation of aripiprazole. In the letter, the only issue FDA cited was deficiencies from a recent inspection of a third-party supplier of sterile water.

Otsuka is working closely with the third-party supplier to resolve the issue as quickly as possible and is planning further discussions with the agency to determine next steps.

----- End of the document-----